Feasibility study of scalp cooling device for risk reduction of alopecia in patients with breast cancer

Feasibility study of scalp cooling device for risk reduction of alopecia in patients with breast cancer - Feasibility study of scalp cooling device for risk reduction of alopecia in patients with breast cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031592

Enrollment

Registered

2018-03-06

Start date

2018-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Scalp cooling is performed from 30 min before start until 90 min (25 min for taxanes) after the end. Pictures of scalp are taken at the time of each course start.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Diagnosed as primary breast cancer Stage I to III Patients scheduled to receive preoperative or postoperative adjuvant chemotherapy containing anthracycline and/or taxanes.

Exclusion criteria

Exclusion criteria: Patients with blood malignancy (leukemia, non-Hodgikin lymphoma, other systemic lymphoma) Patients with cold allergy Any other reasons judged as inadequate to participate in this study by physicians.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with CTCAE grade0-1 alopecia after the completion of all cycles of chemotherapy	—

Secondary

Measure	Time frame
Safety Quality of life Wig or cap use Proportion of patients with grade0-1 alopecia after the completion of all cycles of chemotherapy distinguished by anthracycline(AC) and taxane	—

Countries

Japan

Contacts

Public ContactAkira HIrano

Tokyo Women's Medical University Department of Breast Surgery, Medical Center East

hirano.akira@twmu.ac.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026